Biotest separates from CEO Peter Janssen: Restart in difficult times!

Biotest separates from CEO Peter Janssen: Restart in difficult times!

Dreieich, Deutschland - On May 28, 2025, Biotest AG announced that it separates from its CEO Peter Janssen. This decision comes after three years in which Janssen worked in the company. He had previously been appointed to the board in 2022 and was appointed CEO in January 2024. The separation was "in mutual agreement" and was published in an ad hoc announcement.

Janssen, the previous COO for commercial and industrial operations, brought extensive experience that he gained during his time at Prothya and Pfizer. The Biotest Supervisory Board expressly thanks for the cooperation they have achieved. For 2025 and 2026, however, Biotest expects high losses that are said to be between 55 and 75 million euros. These negative forecasts are related to the current geopolitical challenges, in particular the conflict in the Middle East, and economic instability.

new CEO and restructuring

With immediate effect, Dr. Jörg Schüttrumpf as the successor to Peter Janssen to the CEO and member of the board. Schüttrumpf was part of the board of Biotest from January 2022 to August 2024 and then gained experience with the parent company Grifols. From June 1, 2025, Dirk Neumüller, the previous head of controlling, will subsequently take responsibility for this department, while the HR manager Miriam Oehme will take on his previous tasks in corporate communication.

biotest is an important provider of biological drugs that are obtained from human plasma. The company specializes in clinical immunology, hematology as well as intensive and emergency medicine. It develops and markets products such as immunoglobulins, coagulation factors and albumin and employs more than 2,500 people worldwide. Since May 2022, Biotest has been part of the Grifol's group based in Barcelona.

investments and future outlook

Another factor that shapes the current situation of Biotest are the company's significant investments. In recent years, around 600 million euros have been invested in a new production facility in Dreieichenhain, which underlines the efforts to strengthen the market position. The supervisory board and management are now faced with the task of navigating the company through these challenging times and developing innovative solutions that address the financial loss forecasts.

The current developments at Biotest, especially the change on the board, mark a turning point for the company, which has to adapt to the future challenges in a complex market. The latest personnel changes and strategic decisions are crucial to ensure future competitiveness.

Further information on corporate management and the current developments can be found at op-online , Biotest and Sharewise .